Paper39459407
Amikacin Liposomal Inhalation Suspension for Non-Tuberculous Mycobacteria Lung Infection: A Greek Observational Study.
Loukeri AA and 6 others. Medicina (Kaunas), 2024. Cited by 10 papers, by iCite.
Cite this record
ConductScience Library. Amikacin Liposomal Inhalation Suspension for Non-Tuberculous Mycobacteria Lung Infection: A Greek Observational Study. Papers, record 39459407. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39459407
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Amikacin Liposomal Inhalation Suspension for Non-Tuberculous Mycobacteria Lung Infection: A Greek Observational Study.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Amikacin | Major topic |
| Liposomes | Major topic |
| Anti-Bacterial Agents | Major topic |
| Humans | |
| Male | |
| Female | |
| Aged | |
| Greece | |
| Administration, Inhalation | |
| Middle Aged | |
| Retrospective Studies | |
| Mycobacterium Infections, Nontuberculous | |
| Lung Diseases | |
| Treatment Outcome | |
| Aged, 80 and over |
Source PubMed
References25
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30880280 | M ycobacterium abscessus pulmonary disease: individual patient data meta-analysis. | Eur Respir J | 2019 | https://conductscience.org/library/papers/30880280 | PubMed |
| 2 | 34036184 | Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease. | J Clin Tuberc Other Mycobact Dis | 2021 | https://conductscience.org/library/papers/34036184 | PubMed |
| 3 | 32322600 | Clinical Management of Respiratory Adverse Events Associated With Amikacin Liposome Inhalation Suspension: Results From a Patient Survey. | Open Forum Infect Dis | 2020 | https://conductscience.org/library/papers/32322600 | PubMed |
| 4 | 17277290 | An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. | Am J Respir Crit Care Med | 2007 | https://conductscience.org/library/papers/17277290 | PubMed |
| 5 | 28582488 | Treatment Outcomes of Mycobacterium avium Complex Lung Disease: A Systematic Review and Meta-analysis. | Clin Infect Dis | 2017 | https://conductscience.org/library/papers/28582488 | PubMed |
| 6 | 32636299 | Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. | Eur Respir J | 2020 | https://conductscience.org/library/papers/32636299 | PubMed |
| 7 | 27748623 | Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease. | Am J Respir Crit Care Med | 2017 | https://conductscience.org/library/papers/27748623 | PubMed |
| 8 | 28954780 | Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype. | Eur Respir J | 2017 | https://conductscience.org/library/papers/28954780 | PubMed |
| 9 | 38329686 | Drugs for treating infections caused by non-tubercular mycobacteria: a narrative review from the study group on mycobacteria of the Italian Society of Infectious Diseases and Tropical Medicine. | Infection | 2024 | https://conductscience.org/library/papers/38329686 | PubMed |
| 10 | 30877642 | Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease. | Drugs | 2019 | https://conductscience.org/library/papers/30877642 | PubMed |
| 11 | 35924016 | Early-Phase Adverse Effects and Management of Liposomal Amikacin Inhalation for Refractory Mycobacterium avium Complex Lung Disease in Real-World Settings. | Infect Drug Resist | 2022 | https://conductscience.org/library/papers/35924016 | PubMed |
| 12 | 36140237 | Lipid-Based Drug Delivery Systems for Diseases Managements. | Biomedicines | 2022 | https://conductscience.org/library/papers/36140237 | PubMed |
| 13 | 29337230 | Cholesterol modulates the liposome membrane fluidity and permeability for a hydrophilic molecule. | Food Chem Toxicol | 2018 | https://conductscience.org/library/papers/29337230 | PubMed |
| 14 | 36463137 | Impact of initiation of amikacin liposome inhalation suspension on hospitalizations and other healthcare resource utilization measures: a retrospective cohort study in real-world settings. | BMC Pulm Med | 2022 | https://conductscience.org/library/papers/36463137 | PubMed |
| 15 | 33723805 | Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use. | Clin Drug Investig | 2021 | https://conductscience.org/library/papers/33723805 | PubMed |
| 16 | 34541338 | Challenges of diagnosing and treating non-tuberculous mycobacterial pulmonary disease [NTM-PD]: A case series. | J Clin Tuberc Other Mycobact Dis | 2021 | https://conductscience.org/library/papers/34541338 | PubMed |
| 17 | 36244600 | Global trends of pulmonary infections with nontuberculous mycobacteria: a systematic review. | Int J Infect Dis | 2022 | https://conductscience.org/library/papers/36244600 | PubMed |
| 18 | 23598956 | The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. | Eur Respir J | 2013 | https://conductscience.org/library/papers/23598956 | PubMed |
| 19 | 34289985 | Liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections. | Eur Respir Rev | 2021 | https://conductscience.org/library/papers/34289985 | PubMed |
| 20 | 29867826 | Amikacin Liposome Inhalation Suspension (ALIS) Penetrates Non-tuberculous Mycobacterial Biofilms and Enhances Amikacin Uptake Into Macrophages. | Front Microbiol | 2018 | https://conductscience.org/library/papers/29867826 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42667005 | Amikacin Liposomal Inhalation Suspension: Advances in Application Against Refractory Mycobacterium avium Complex. | Infect Drug Resist | 2026 | https://conductscience.org/library/papers/42667005 | PubMed |
| 42638634 | Bidirectional pathogenesis between non-tuberculous mycobacteria and bronchiectasis: clinical insights, diagnostic challenges and future directions-Perspectives from South Asia. | Front Tuberc | 2025 | https://conductscience.org/library/papers/42638634 | PubMed |
| 42076080 | pH-Responsive Nanostructured Calcium Phosphate Microrods as Pulmonary Delivery Platform: Fabrication, Characterization, and Comparative Assessment of Cytotoxic and Transcriptomic Responses in Alveolar Macrophages. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42076080 | PubMed |
| 41408185 | Mycobacterium florentinum pulmonary disease: a case report and review of the literature. | BMC Infect Dis | 2025 | https://conductscience.org/library/papers/41408185 | PubMed |
| 41304232 | Epidemiology and Drug Susceptibility of Nontuberculous Mycobacteria in the Province of Pavia (Northern Italy): An Overview. | Microorganisms | 2025 | https://conductscience.org/library/papers/41304232 | PubMed |
| 40724029 | Liposome-Encapsulated Antibiotics for the Therapy of Mycobacterial Infections. | Antibiotics (Basel) | 2025 | https://conductscience.org/library/papers/40724029 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39459407
GET https://conductscience.org/api/papers/v1/39459407/references?page=2